AZ to acquire Actavis’ US respiratory portfolio

AstraZeneca to acquire rights to actavis' Branded respiratory portfolio in THE
US AND CANADA

Agreement strengthens AstraZeneca's aclidinium respiratory franchise and adds
immediate revenues with long-term growth potential

AstraZeneca and Actavis Plc today announced that they have entered into a
definitive agreement under which AstraZeneca will acquire the rights to Actavis'
branded respiratory business in the US and Canada for an initial consideration
of $600 million on completion and low single-digit royalties above a certain
revenue threshold.

Upon completion of the transaction, AstraZeneca will own the development and
commercial rights in the US and Canada to TudorzaTM PressairTM (aclidinium
bromide inhalation powder), a twice-daily long-acting muscarinic antagonist
(LAMA) for chronic obstructive pulmonary disease (COPD), and Daliresp®
(roflumilast), the only once-daily oral PDE4 inhibitor currently on the market
for COPD. AstraZeneca will also own development rights in the US and Canada for
LAS40464, the combination of a fixed dose of aclidinium with formoterol long
acting beta agonist (LAMA/LABA) in a dry powder inhaler, which is approved in
the EU under the brand name Duaklir® Genuair®.

The strategic transaction strengthens AstraZeneca's respiratory franchise
globally and builds on the acquisition of Almirall's respiratory portfolio in
2014 by extending the company's development and commercialisation rights into
the US for both Tudorza Pressair and Duaklir Genuair. The acquisition of Tudorza
Pressair and Daliresp will immediately add on-market revenues and complements
AstraZeneca's respiratory portfolio by broadening the choice of treatments and
formulations offered to patients and physicians. The two products had combined
annual sales in the US of approximately $230 million in 2014.

AstraZeneca will also pay Actavis an additional $100 million and Actavis has
agreed to a number of contractual consents and approvals, including certain
amendments to the ongoing collaboration agreements between AstraZeneca and
Actavis.

Paul Hudson, President, AstraZeneca US and Executive Vice President, North
America, AstraZeneca, said: "Our agreement with Actavis builds on our
acquisition of Almirall's respiratory portfolio and brings long-term value to
one of our key growth platforms. With the addition of Tudorza and Daliresp, we
will benefit from an immediate boost to revenue in our biggest market, further
strengthening our growing respiratory franchise. This combined portfolio helps
us to offer an even broader range of innovative treatments and formulations to
physicians and pulmonary specialists for patients suffering with COPD."

Brent Saunders, CEO and President of Actavis, said: "This divestiture will
permit Actavis to sharpen our strategic focus and sales and marketing activities
on our larger, core therapeutic categories in CNS, Women's Health, Urology, GI,
Anti-infectives and Cardiovascular, as well as in Dermatology/Aesthetics and
Ophthalmology, which will be added to our global brand portfolio following the
completion of the Allergan acquisition later this year. It will also enhance our
options in the near term to invest in further expansion through business
development or accelerate debt repayment. The decision to divest these brand
respiratory products will have no impact on our commitment to investing in and
developing our generic respiratory product line."

The transaction is subject to antitrust law clearance as well as other customary
terms and conditions. It is anticipated that the transaction will complete in
the first quarter of 2015.

NOTES TO EDITORS

About Tudorza Pressair
Tudorza Pressair (aclidinium bromide inhalation powder) 400 mcg is an
anticholinergic indicated for the long-term maintenance treatment of
bronchospasm associated with chronic obstructive pulmonary disease (COPD),
including chronic bronchitis and emphysema. When given by inhalation, aclidinium
produces bronchodilation by inhibiting the muscarinic M3 receptor in the airway
smooth muscle. Aclidinium is rapidly hydrolyzed in human plasma into two major
inactive metabolites.

Tudorza is administered using a multiple-dose dry powder inhaler, Pressair,
which delivers 60 doses of aclidinium bromide powder for inhalation. The
Pressair inhaler has a colored control window and audible "click" which confirm
successful inhalation of the dose and a dose indicator to let patients know how
many doses remain in the inhaler.

About Daliresp
Daliresp (500mcg) is a selective PDE4 inhibitor that is indicated as a treatment
to reduce the risk of exacerbations in patients with severe COPD associated with
chronic bronchitis and a history of exacerbations. Daliresp is a once-daily oral
tablet and is the first and only selective PDE4 inhibitor approved by the FDA.

While the specific mechanism by which Daliresp exerts its therapeutic action in
COPD patients is not well defined, it is thought to be related to the effects of
increased intracellular cyclic AMP in the lung cells. Daliresp is not a steroid,
is not a bronchodilator and is not indicated for the relief of acute
bronchospasm.

About COPD
COPD (chronic obstructive pulmonary disease) is a progressive disease associated
mainly with tobacco smoking, air pollution or occupational exposure, which can
cause obstruction of airflow in the lungs resulting in debilitating bouts of
breathlessness. It affects an estimated 300 million people worldwide and is
predicted to be the third leading cause of death by 2020. Although COPD is
widely regarded as a disease of the elderly, 50 per cent of patients are
estimated to be between 50 and 65 years of age, meaning half of the COPD
population is likely to be affected at a stage in their life when they are at
the peak of their earning potential and are likely to have major family
responsibilities.

About Actavis
Actavis Plc (NYSE:ACT), headquartered in Dublin, Ireland, is a unique specialty
pharmaceutical company focused on developing, manufacturing and commercializing
high quality affordable generic and innovative branded pharmaceutical products
for patients around the world.

Actavis markets a broad portfolio of branded and generic pharmaceuticals and
develops innovative medicines for patients suffering from diseases principally
in the central nervous system, gastroenterology, women's health, urology,
cardiovascular, respiratory and anti-infective therapeutic categories. The
Company is an industry leader in product research and development, with one of
the broadest brand development pipelines in the pharmaceutical industry, and a
leading position in the submission of generic product applications. Actavis has
commercial operations in more than 60 countries and operates more than 30
manufacturing and distribution facilities around the world.

For more information, visit Actavis' website at www.actavis.com.

Actavis Forward-Looking Statement
Statements contained in this press release that refer to future events or other
non-historical facts are forward-looking statements that reflect Actavis'
current perspective of existing trends and information as of the date of this
release. Except as expressly required by law, Actavis disclaims any intent or
obligation to update these forward-looking statements. Actual results may differ
materially from Actavis' current expectations depending upon a number of factors
affecting Actavis' business. These factors include, among others, the difficulty
of predicting the timing or outcome of FDA approvals or actions, if any; the
impact of competitive products and pricing; market acceptance of and continued
demand for Actavis' products; difficulties or delays in manufacturing; and other
risks and uncertainties detailed in Actavis' periodic public filings with the
Securities and Exchange Commission, including but not limited to Actavis'
Quarterly Report on Form 10-Q for the quarter ended September 30, 2014. Except
as expressly required by law, Actavis disclaims any intent or obligation to
update these forward-looking statements.

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media Enquiries

Esra Erkal-Paler                     +44 20 7604 8030 (UK/Global)
Vanessa Rhodes                    +44 20 7604 8037 (UK/Global)
Ayesha Bharmal                     +44 20 7604 8034 (UK/Global)
Michele Meixell                       +1 302 885 2677 (US)
Jacob Lund                             +46 8 553 260 20 (Sweden)

Investor Enquiries
Thomas Kudsk Larsen           +44 20 7604 8199       mob: +44 7818 524185
Karl Hård                                +44 20 7604 8123    mob: +44 7789
654364
Eugenia Litz                           +44 20 7604 8233       mob: +44 7884
735627
Craig Marks                            +44 20 7604 8591       mob: +44 7881
615764
Christer Gruvris                      +44 20 7604 8126       mob: +44 7827
836825

5 February 2015

-ENDS-